You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22

Citation Tools

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Musacchio L, Turinetto M, Bartoletti M, et al
2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22
International Journal of Gynecologic Cancer 2022;32:A355.